OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in Lipidology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)

Article	Citations
Sphingomyelins and ceramides: possible biomarkers for dementia?	65
Genetic variation in apolipoprotein A-V in hypertriglyceridemia	61
Angiopoietin-like protein 8: a multifaceted protein instrumental in regulating triglyceride metabolism	60
Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review	59
Alveolar macrophages: guardians of the alveolar lipid galaxy	46
ANGPTL4: a new mode in the regulation of intravascular lipolysis	43
Editorial introductions	39
Familial hypercholesterolemia-Plus: is the metabolic syndrome changing the clinical picture of familial hypercholesterolemia?	35
Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease	34
Implementation science and genetic testing for familial hypercholesterolemia	32
The lipid-heart hypothesis from the Seven Countries Study of Cardiovascular Diseases	32
Universal screening for familial hypercholesterolaemia: how can we maximise benefits and minimise potential harm for children and their families?	30
Lipid metabolism during pregnancy: consequences for mother and child	29
Exosomes and lipid metabolism in metabolic and cardiovascular disorders	22
Familial hypercholesterolemia: The nexus of endothelial dysfunction and lipoprotein metabolism in COVID-19	19
Familial hypercholesterolemia in children and the importance of early treatment	18
Lipoprotein(a) and peripheral artery disease: contemporary evidence and therapeutic advances	17
Oxidized LDL receptors: a recent update	17
Nonalcoholic fatty liver disease: an update	16
Genetic determinants of pancreatitis risk in hypertriglyceridemia	16
Editorial introductions	16
A new SPRING in lipid metabolism	15
The current state of apolipoprotein E in dyslipidemia	15
Splice correction therapies for familial hypercholesterolemic patients with low-density lipoprotein receptor mutations	15
The complex pro-atherosclerotic role of lipoprotein(a): a multiplicity of cellular targets	14

The need for national and international registries of patients with elevated lipoprotein(a)	14
Familial hypercholesterolemia in pregnancy	14
Editorial introduction	14
Nutrition and its impact on cardiovascular disease	14
The intracellular chylomicron highway: novel insights into chylomicron biosynthesis, trafficking, and secretion	14
APOE and familial hypercholesterolemia	13
High-density lipoprotein functionality, cardiovascular health, and patterns of alcohol consumption: new insights and future perspectives	13
ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?	13
From clinical development to real-world outcomes with inclisiran	13
Are the lipid-lowering effects of incretin-based therapies relevant for cardiovascular benefit?	12
Inclisiran: present and future perspectives of a new effective LDL cholesterol-lowering agent	12
Can small dense LDL cholesterol be estimated from the lipid profile?	12
Editorial introductions	11
Recent dynamic studies of the metabolism of atherogenic lipoproteins: elucidating the mode of action of new therapies	11
The emerging role of fat-inducing transcript 2 in endoplasmic reticulum proteostasis and lipoprotein biogenesis	11
Beyond cholesterol: linking the conformation of apolipoprotein B to atherogenesis	10
Cardiomyocytes, sphingolipids and cardio myotoxicity	10
Distinct roles of size-defined HDL subpopulations in cardiovascular disease	10
Newborn screening for lipid disorders	10
The expanding role of lyso-phosphatidylcholine acyltransferase-3 (LPCAT3), a phospholipid remodeling enzyme, in health and disease	10
In the wake of the Scandinavian Simvastatin Survival Study trial	10
Association of dietary patterns and components with atherosclerosis risk biomarkers in familial hypercholesterolemia	9
Pregnancy, cardiovascular health, and microchimerism	9
Genetic testing for familial hypercholesterolemia	9
Altered cardiovascular risk pattern of LDL cholesterol in older adults	9
Preprint servers in lipidology: current status and future role	9
Strategies for management of patients with elevated lipoprotein(a)	9
Clinical associations between exercise and lipoproteins	8
Prevention of cardiometabolic diseases through dietary modifications	8
Circulating protein and lipid markers of early sepsis diagnosis and prognosis: a scoping review	8
Assessment of cardiovascular disease risk: a 2023 update	7
Genotype–phenotype correlation in a large cohort of pediatric patients with heterozygous and homozygous familial hypercholesterolemia	7
Navigating variants of uncertain significance in genetic dyslipidemia: how to assess and counsel patients	7
The pathophysiology of excess plasma-free cholesterol	7
Sphingosine-1-phosphate: metabolism, transport, atheroprotection and effect of statin treatment	7
Dietary fat, telomere length and cognitive function: unravelling the complex relations	6
The feedback cycles between glucose, amino acids and lipids and alpha cell secretion and their role in metabolic fatty liver disease	6
Editorial introductions	6
Clonal hematopoiesis of indeterminate potential and the evolutionary lottery in chromosome 2: does that make human atherosclerosis special?	6
A contemporary snapshot of familial hypercholesterolemia registries	6
Predictors of cardiovascular risk in familial hypercholesterolemia	5
How should low-density lipoprotein cholesterol be calculated in 2022?	5
Therapeutic application of genome editing in dyslipidemia	5
Recent lipoprotein(a) trials	5
Diagnosis of remnant hyperlipidaemia	5
Lipidomics in gestational diabetes mellitus	5
Atherogenic low-density lipoprotein and cardiovascular risk	5
Remnant cholesterol as a new lipid-lowering target to reduce cardiovascular events	5
Proprotein convertase subtilisin/kexin type 9-inhibition across different patient populations	5
Translating guidelines into practice via implementation science: an update in lipidology	5

Dietary factors and brain health	5
Understanding the ins and outs of lipoprotein (a) metabolism	4
Genetics of remnant cholesterol	4
Consensus and guidelines on lipoprotein(a) – seeing the forest through the trees	4
Basic and translational evidence supporting the role of TM6SF2 in VLDL metabolism	4
Resolution of apolipoprotein A1 and A2 proteoforms: their cardiometabolic correlates and implications for future research	4
Regulation of cardiovascular calcification by lipids and lipoproteins	4
Bempedoic acid for nonalcoholic fatty liver disease: evidence and mechanisms of action	4
Triglyceride-rich lipoprotein cholesterol and cardiovascular risk	4
Are Lipoprotein(a) levels decreased in insulin resistance and type 2 diabetes?	4
Established and potential cardiovascular risk factors in metabolic syndrome: Effect of bariatric surgery	4
Editorial introductions	3
Orticumab: the potential to harness oxidized LDL to reduce coronary inflammation with plaque-targeted therapy	3
Cholesteryl ester transfer protein inhibition: a pathway to reducing risk of morbidity and promoting longevity	3
Bempedoic acid: new evidence and recommendations on use	3
G protein-coupled receptor 146: new insights from genetics and model systems	3
Polygenic contribution for familial hypercholesterolemia (FH)	3
Novel therapeutic opportunities for familial lecithin:cholesterol acyltransferase deficiency: promises and challenges	3
Editorial introduction	3
Macrophage SR-B1 in atherosclerotic cardiovascular disease	3
Lipids and brain inflammation in APOE4-associated dementia	3
Dyslipidemia and aortic valve disease	3
Circulating cell-free DNA and its association with cardiovascular disease: what we know and future perspectives	3
Inflammation in atherosclerosis: a Big Idea that has underperformed so far	3
Complex actions of sodium glucose transporter-2 inhibitors on lipids, calcific atherosclerosis, and bone density	3
Fatty acid metabolism in cancer cells – the power of plasticity	3
PCSK9-directed therapies: an update	3
Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction	2
Editorial introductions	2
Editorial introduction	2
Proprotein convertase subtilisin/kexin type 9 as a drug target for abdominal aortic aneurysm	2
Ketogenic therapies in mild cognitive impairment and dementia	2
Lipoprotein (a) in familial hypercholesterolaemia	2
Cycling of metabolic states and metabolites as drivers of atherosclerosis	2
Brain lipid metabolism: the emerging role of lipid droplets in glial cells	2
Angiopoietin-like 3 inhibition and the liver: less is more?	2
Macrophage cannibalism: efferocytosis in atherosclerosis	2
Updates on genetics and molecular biology	2
Familial combined hyperlipidemia is a polygenic trait	2
Lipidome and inflammation interplay: the role of diet in this relationship	2